## PODD: Insulet Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%); PEG 2.19 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($269.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference**
- Source: BioSpace | 20251217T113139 | Neutral | Relevance: 100%
- Insulet Corporation announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco. The presentation regarding their Omnipod tubeless insulin pump technology will be webcast live and available for replay on their investor relations website. Insulet is a medical device company focused on simplifying diabetes management and leveraging its Omnipod platform for various therapeutic areas.

**2. Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference**
- Source: 01net | 20251216T150851 | Neutral | Relevance: 100%
- Insulet Corporation announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company, a leader in tubeless insulin pump technology with its Omnipod brand, will make the presentation available via webcast on its investor relations website. Insulet provides innovative medical devices to simplify life for people with diabetes.

**3. Evercore ISI initiates Insulet stock with Outperform rating, $370 price target**
- Source: Investing.com UK | 20251216T120906 | Bullish | Relevance: 100%
- Evercore ISI has initiated coverage on Insulet Corporation (NASDAQ:PODD) with an Outperform rating and a $370 price target, citing the company's market leadership in the underpenetrated insulin pump market. The firm highlighted Insulet's strong execution, unique tubeless design, and broad pharmacy access as key competitive advantages, predicting over 20% growth and significant EPS expansion through 2028. This positive outlook is supported by recent FDA clearance for Omnipod 5 enhancements and expanding recycling programs.

**4. Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference**
- Source: Business Wire | 20251216T120850 | Somewhat-Bullish | Relevance: 100%
- Insulet Corporation announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 11:15 a.m. (Pacific Time). A live webcast and replay of the presentation will be available on the Insulet Investor Relations website. Insulet is a medical device company specializing in tubeless insulin pump technology with its OmnipodÂ® brand.

**5. Evercore ISI initiates Insulet stock with Outperform rating, $370 price target**
- Source: Investing.com | 20251216T120831 | Bullish | Relevance: 100%
- Evercore ISI has initiated coverage on Insulet Corporation (NASDAQ:PODD) with an Outperform rating and a $370 price target, citing the company's market leadership, strong execution, and competitive advantages in the underpenetrated insulin pump market. Analysts forecast over 20% growth and strong EPS expansion for Insulet, which maintains excellent financial health and has recently expanded its Pod recycling program and received FDA clearance for Omnipod 5 enhancements. This positive outlook is echoed by other firms like TD Cowen and UBS, who also hold Buy ratings for Insulet.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Canaccord Genui | $450 | $432 | +4% |
| 2025-12-16 | Evercore ISI Gr | $370 | $0 | 0% |
| 2025-11-24 | Canaccord Genui | $432 | $428 | +1% |
| 2025-11-21 | Truist Securiti | $412 | $390 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-16 | Evercore ISI Gr | init | Outperform |
| 2025-11-24 | Canaccord Genui | main | Buy |
| 2025-11-21 | Truist Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.30M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+1.0%)
- FMR, LLC: 10.8% (+0.8%)
- Blackrock Inc.: 9.4% (+2.8%)
- Capital Research Glo: 6.5% (-4.0%)
- State Street Corpora: 4.4% (+1.1%)

### Key Risks

1. Premium valuation (P/E 47x, PEG 2.2x) vulnerable to multiple compression.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +5%) could attract flows.
- Momentum building: MRS_10 improving +4.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.19 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.9x). Revenue growth strong at 20% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.4B |
| Beta | 1.38 |
| 52W Range | $230.05 - $354.88 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.19 |
| Forward P/E | 46.8 |
| Current P/E | 59.2 |
| YoY Growth | 26.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -4.1% to 0.5% (+4.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Below SMA200 (0.96x), long-term trend not supportive. MACD histogram bearish (-2.30), momentum weakening. OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.47% (CS: 31) | Neutral |
| RSI_14 | 35.7 | Neutral |
| MACD Histogram | -2.30 | Bearish |
| vs SMA20 | 0.934x | Below |
| vs SMA50 | 0.913x | Below |
| vs SMA200 | 0.961x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $289.57
- **Stop Loss:** $269.23 (7.0% risk)
- **Target:** $309.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 53
- **Position Value:** $15,347.21
- **Portfolio %:** 15.35%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-19 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.24 | +8.1% |
| 2025Q2 | $0.92 | $1.17 | +26.8% |
| 2025Q1 | $0.79 | $1.02 | +29.7% |
| 2024Q4 | $1.02 | $1.15 | +12.6% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*